Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Background: Effectiveness of Percutaneous transluminal angioplasty and stenting (PTAS) on
prevention of events of stroke and death in patients with symptomatic intracranial
atherosclerosis (ICAS) is controversial.
Aim: to determine whether PTAS plus medical treatment (MT) are superior to MT alone in
preventing events of stroke and death in patients with symptomatic ICAS.
Methods: The investigators will carry out a randomized controlled trial in 3 hospitals in
China. A total of 198 patients with ICAS will be randomized into 2 groups: PTAS+MT and MT
group. All patients will receive aspirin (100 mg daily) and clopidogrel (75 mg daily)
immediately after randomization, and patients in PTAS+MT group will receive surgery within 5
days after randomization. The patients will be followed up for 1 year after randomization and
assessed for events of stroke and death at 30 days and 1 year after randomization, the
incidence of recurrent ischaemic stroke in the stenting-involved vascular territory at 30
days and 1 year after randomization, incidence of in-stent restenosis at 1 year after
randomization,etc.